Chronic Kidney Disease Requiring Chronic Dialysis Clinical Trial
— IRTHEPOfficial title:
Effect of Intradialytic Resistance Training on Circulatory miRNA Profile and Muscle Strength in Haemodialysis Patients
Verified date | March 2020 |
Source | Pavol Jozef Safarik University |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The study will investigate the effects of an intradialytic resistance training on miRNA´s expression and muscle strength in haemodialysis patients.
Status | Completed |
Enrollment | 90 |
Est. completion date | January 31, 2020 |
Est. primary completion date | January 31, 2020 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 30 Years and older |
Eligibility |
Inclusion Criteria: - All patients over 30 years of age, diagnosed with chronic kidney disease, treated with haemodialysis are eligible for our study. Exclusion Criteria: - Lower extremity amputation, severe dementia or retardation, acute intercurrent disease and probability of one year mortality higher than 25 % according to Charlson Comorbidity Index (CCI) are the exclusion criteria for participation in the study. |
Country | Name | City | State |
---|---|---|---|
Slovakia | Fresenius Medical Care - Dialysis Services Košice, Slovakia | Košice |
Lead Sponsor | Collaborator |
---|---|
Pavol Jozef Safarik University | Dialysis Services Fresenius Medical Care Slovakia, Private Health Institution Logman - Logman East |
Slovakia,
Smart NA, Williams AD, Levinger I, Selig S, Howden E, Coombes JS, Fassett RG. Exercise & Sports Science Australia (ESSA) position statement on exercise and chronic kidney disease. J Sci Med Sport. 2013 Sep;16(5):406-11. doi: 10.1016/j.jsams.2013.01.005. Epub 2013 Feb 21. Review. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Satisfaction with Life Scale | The Satisfaction With Life Scale will be used for measurements of the life satisfaction component of subjective well-being. | 1-5 days before the intervention | |
Other | Multidimensional Scale of Perceived Social Support | The Multidimensional Scale of Perceived Social Support will be used to measure how much support a parent feels they get from family, friends and significant others. | 1-5 days before the intervention | |
Other | Health literacy | The Health literacy level will be assessed using The Health Literacy Questionnaire and The Brief Health Literacy survey. This questionnaire comprises nine domains to provide a detailed profile of health literacy of populations, groups or patients of interest. The HLQ is divided into two parts which differ in response categories. Part 1 (domains 1-5) has 4 response categories rating the extent of agreement from 1 to 4. Part 2 (domains 6-9) has 5 response categories rating the level of difficulty from cannot do or always difficult (1), to always easy (5). Each domain was scored as the average of the item scores. The score ranges from 1 to 4 or 1 to 5 respectively, a higher score indicating higher level of health literacy. | 1-5 days before the intervention | |
Other | Karnofsky Performance Status | The Karnofsky Performance Status (KPS) scale will be used to assess self-sufficiency and functional capacity of patients on haemodialysis. KPS determines functional impairment in the performance of activities of daily living. | 1-5 days before the intervention | |
Other | Subjective Global Assessment | The nutritional status of patients will be assessed by Subjective Global Assessment method. | 1-5 days before the intervention | |
Primary | Change in lower extremity muscle strength | Change in maximal voluntary force produced during knee extension, leg flexion, extension and hip abduction, adduction will be assessed by dynamometer | Before the intervention, 1-5 days after the completion of the 12-week intervention and after 3 months follow up | |
Secondary | Change in activity of circulatory miRNA molecules involved in TRIM63 and IGF-1 signalling pathways | Blood plasma will be collected for miRNAs analysis. We will analyze the activity of miRNAs involved in TRIM63 and IGF-1 signalling pathways for better definitions of chronic renal insufficiency and muscular adaptation following progressive resistance training. For miRNA analysis, we selected circulatory miRNA´s which were previously connected with regulation of calcium metabolism, calcification processes, protein-energy wasting, muscle mass and functions | Before the intervention and 1-5 days after the completion of 12-week intervention | |
Secondary | Change in renal specific clinical data | Clinical data will be collected from the medical documentation of patients. The extracted database will contain patient´s nephrological diagnosis profile, data about the presence of other diagnosis and comorbidities, body composition parameters and standard dialysis biochemistry, haematology and dialysis adequacy measures. | Before the intervention, 1-5 days after the completion of the 12-week intervention and after 3 months follow up | |
Secondary | Change in score on the Hospital Anxiety and Depression Scale | The Hospital Anxiety and Depression Scale (HADS) will be used to assess states of depression and anxiety in the setting of a hospital medical outpatient clinic. The HADS consists of two subscales, subscale for anxiety and subscale for depression. Both subscales contains seven items and each item is rated on a four-point scale (numeric score range from 0 to 3 points). Maximal score for both subscales is 21, minimal score is 0. Scores of 11 or more on either subscale are considered to be a significant indicator of psychological morbidity. Scores between 8 and 10 represents "borderline" and scores between 0 and 7 represents "normal" indication of anxiety and depression. | Before the intervention and 1-5 days after the completion of 12-week intervention | |
Secondary | Change in score on the Kidney Disease Quality of Life | Kidney Disease Quality of Life (KDQOL™) instrument will be used to assess generic and kidney-disease targeted aspects of quality of life (self-rated health, self-rated change of health status, physical and mental component) of patients on haemodialysis. | Before the intervention and 1-5 days after the completion of 12-week intervention |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05700851 -
Immuno-nutrition Supplementation in Haemodialysis
|
N/A | |
Recruiting |
NCT02616627 -
Association Between DXA Results and the Complications, Clinical Courses and Outcomes in Chronic Dialysis Patients
|
||
Completed |
NCT01464190 -
A Phase 3 Extension Study to Investigate the Long-term Safety, Tolerability and Efficacy of PA21, a Phosphate Binder in Dialysis Patients
|
Phase 3 | |
Recruiting |
NCT06040281 -
Smart and Fit for Kidney Transplantation
|
N/A | |
Active, not recruiting |
NCT03535922 -
Evaluation of Routinely Measured Patient-reported Outcomes in Hemodialysis Care
|
N/A | |
Completed |
NCT04622709 -
Pilot Study of Loop Diuretics Among Individuals Receiving Hemodialysis
|
Phase 2 | |
Completed |
NCT04585607 -
Potential Benefits of Expanded Hemodialysis in Prevention of Sarcopenia
|
Phase 4 | |
Completed |
NCT03182699 -
Effect of Etelcalcetide on Cardiac Hypertrophy in Hemodialysis Patients
|
Phase 4 | |
Completed |
NCT03942744 -
The Effect of High-flux Hemodialysis and On-line Hemodiafiltration on Endothelial Function.
|
N/A | |
Completed |
NCT04549597 -
Study to Evaluate the Use of Tenapanor as Core Therapy in the Treatment of Hyperphosphatemia
|
Phase 4 | |
Recruiting |
NCT04659525 -
Evolocumab Plus Ezetimibe in Haemodialized Statin-intolerant Patients With Hypercholesterolemia
|
Phase 4 | |
Completed |
NCT04125537 -
Pathways Project: Kidney Supportive Care
|
||
Recruiting |
NCT03347773 -
Oral Nutritional Supplement Intervention Among Hemodialysis Patients With Sarcopenic Obesity
|
N/A | |
Recruiting |
NCT04397653 -
Evolocumab Plus Ezetimibe in High Risk Haemodialized Statin Intolerant Patients
|
Phase 4 | |
Active, not recruiting |
NCT03938285 -
Effect of Hemodiafiltration Plus MCOs on Uremic Toxins Removal
|
N/A | |
Completed |
NCT03525223 -
Modulation of Tissue Sodium in Hemodialysis Patients
|
N/A | |
Completed |
NCT01324128 -
A Phase 3 Study to Investigate the Safety and Efficacy of PA21, a Phosphate Binder, in Dialysis Patients
|
Phase 3 | |
Not yet recruiting |
NCT04600193 -
a Randomized Controlled Trial of the Intake of Organic and Inorganic Phosphate in Peritoneal Dialysis Patients
|
N/A | |
Not yet recruiting |
NCT06225544 -
Lumasiran in Hyperoxalaemic Patients on Haemodialysis
|
Phase 2 | |
Recruiting |
NCT05209880 -
Advance Care Planning in the Emergency Department
|
N/A |